S&P 500   4,076.57
DOW   34,395.01
QQQ   293.72
Is Apple Going To Rally Into Year End?
Shark Tank Millionaire's Pick - This Tech Stock Could Take Off (Ad)pixel
25 Ways to Improve Your Financial Situation in 1 Hour
La-Z-Boy Reclines To More Comfortable Levels 
A One Stop Shop for Everything Futures Trading (Ad)pixel
Are the Short Sellers Still Right About Mullen Automotive stock? 
Is The Recovery Rally Here For SoFi?
A One Stop Shop for Everything Futures Trading (Ad)pixel
Biden administration presses senators to avert rail strike
Trump Org. defense lawyer scolded for using struck testimony
S&P 500   4,076.57
DOW   34,395.01
QQQ   293.72
Is Apple Going To Rally Into Year End?
Shark Tank Millionaire's Pick - This Tech Stock Could Take Off (Ad)pixel
25 Ways to Improve Your Financial Situation in 1 Hour
La-Z-Boy Reclines To More Comfortable Levels 
A One Stop Shop for Everything Futures Trading (Ad)pixel
Are the Short Sellers Still Right About Mullen Automotive stock? 
Is The Recovery Rally Here For SoFi?
A One Stop Shop for Everything Futures Trading (Ad)pixel
Biden administration presses senators to avert rail strike
Trump Org. defense lawyer scolded for using struck testimony
S&P 500   4,076.57
DOW   34,395.01
QQQ   293.72
Is Apple Going To Rally Into Year End?
Shark Tank Millionaire's Pick - This Tech Stock Could Take Off (Ad)pixel
25 Ways to Improve Your Financial Situation in 1 Hour
La-Z-Boy Reclines To More Comfortable Levels 
A One Stop Shop for Everything Futures Trading (Ad)pixel
Are the Short Sellers Still Right About Mullen Automotive stock? 
Is The Recovery Rally Here For SoFi?
A One Stop Shop for Everything Futures Trading (Ad)pixel
Biden administration presses senators to avert rail strike
Trump Org. defense lawyer scolded for using struck testimony
S&P 500   4,076.57
DOW   34,395.01
QQQ   293.72
Is Apple Going To Rally Into Year End?
Shark Tank Millionaire's Pick - This Tech Stock Could Take Off (Ad)pixel
25 Ways to Improve Your Financial Situation in 1 Hour
La-Z-Boy Reclines To More Comfortable Levels 
A One Stop Shop for Everything Futures Trading (Ad)pixel
Are the Short Sellers Still Right About Mullen Automotive stock? 
Is The Recovery Rally Here For SoFi?
A One Stop Shop for Everything Futures Trading (Ad)pixel
Biden administration presses senators to avert rail strike
Trump Org. defense lawyer scolded for using struck testimony

Pulse Biosciences - PLSE Stock Forecast, Price & News

$1.93
-0.07 (-3.50%)
(As of 12/1/2022 12:00 AM ET)
Add
Compare
Today's Range
$1.85
$1.98
50-Day Range
$1.53
$2.65
52-Week Range
$1.18
$19.65
Volume
87,738 shs
Average Volume
194,712 shs
Market Capitalization
$71.85 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.17

Pulse Biosciences MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
478.6% Upside
$11.17 Price Target
Short Interest
Bearish
15.79% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.60
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
Acquiring Shares
$35,033 Bought Last Quarter
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.98 out of 5 stars

Medical Sector

707th out of 1,047 stocks

Surgical & Medical Instruments Industry

76th out of 104 stocks

PLSE stock logo

About Pulse Biosciences (NASDAQ:PLSE) Stock

Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.

Receive PLSE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pulse Biosciences and its competitors with MarketBeat's FREE daily newsletter.

PLSE Stock News Headlines

Earnings Preview: Pulse Biosciences
Pulse Biosciences, Inc. (PLSE)
Recap: Pulse Biosciences Q2 Earnings
A Preview Of Pulse Biosciences Earnings
See More Headlines
Receive PLSE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pulse Biosciences and its competitors with MarketBeat's FREE daily newsletter.

PLSE Company Calendar

Last Earnings
11/15/2021
Today
12/01/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/30/2023

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:PLSE
Fax
N/A
Employees
142
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$11.17
High Stock Price Forecast
$13.00
Low Stock Price Forecast
$8.50
Forecasted Upside/Downside
+478.6%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
3 Analysts

Profitability

Net Income
$-63,660,000.00
Net Margins
-2,866.34%
Pretax Margin
-4,167.67%

Debt

Sales & Book Value

Annual Sales
$1.42 million
Book Value
$0.17 per share

Miscellaneous

Free Float
18,353,000
Market Cap
$71.85 million
Optionable
Optionable
Beta
1.23

Key Executives

  • Mr. Robert W. Duggan (Age 78)
    Exec. Chairman
  • Ms. Sandra A. Gardiner (Age 56)
    Exec. VP of Fin. & Admin., CFO and Treasurer
    Comp: $417.92k
  • Mr. Darrin R. Uecker (Age 56)
    CTO & Director
    Comp: $511.42k
  • Mr. Mitchell E. Levinson (Age 62)
    Chief Strategy Officer & Director
    Comp: $449.02k
  • Mr. Kevin Danahy (Age 51)
    Pres & CEO
  • Dr. Richard Nuccitelli Ph.D.
    Chief Science Officer
  • Mr. Kenneth B. Stratton Esq. (Age 53)
    J.D., Gen. Counsel & Corp. Sec.
  • Dr. Holly Hartman J.D.
    Ph.D., VP of Bus. Devel. & Corp. Strategy
  • Ms. Patty Perla
    VP of HR
  • Mr. David Danitz
    Sr. VP of Engineering













PLSE Stock - Frequently Asked Questions

Should I buy or sell Pulse Biosciences stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Pulse Biosciences in the last twelve months. There are currently 3 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" PLSE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PLSE, but not buy additional shares or sell existing shares.
View PLSE analyst ratings
or view top-rated stocks.

What is Pulse Biosciences' stock price forecast for 2023?

3 Wall Street analysts have issued 1 year target prices for Pulse Biosciences' shares. Their PLSE share price forecasts range from $8.50 to $13.00. On average, they predict the company's share price to reach $11.17 in the next year. This suggests a possible upside of 478.6% from the stock's current price.
View analysts price targets for PLSE
or view top-rated stocks among Wall Street analysts.

How have PLSE shares performed in 2022?

Pulse Biosciences' stock was trading at $14.81 at the beginning of 2022. Since then, PLSE shares have decreased by 87.0% and is now trading at $1.93.
View the best growth stocks for 2022 here
.

When is Pulse Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 30th 2023.
View our PLSE earnings forecast
.

How were Pulse Biosciences' earnings last quarter?

Pulse Biosciences, Inc. (NASDAQ:PLSE) announced its quarterly earnings results on Monday, November, 15th. The company reported ($0.48) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.53) by $0.05. The firm had revenue of $0.57 million for the quarter. Pulse Biosciences had a negative net margin of 2,866.34% and a negative trailing twelve-month return on equity of 290.24%. During the same period in the prior year, the company earned ($0.51) EPS.

What is Darrin R. Uecker's approval rating as Pulse Biosciences' CEO?

2 employees have rated Pulse Biosciences Chief Executive Officer Darrin R. Uecker on Glassdoor.com. Darrin R. Uecker has an approval rating of 100% among the company's employees. This puts Darrin R. Uecker in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Pulse Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Pulse Biosciences investors own include Advanced Micro Devices (AMD), AbbVie (ABBV), Bausch Health Companies (BHC), Wayfair (W), Achaogen (AKAO), NVIDIA (NVDA), Portola Pharmaceuticals (PTLA), Enphase Energy (ENPH) and Novavax (NVAX).

When did Pulse Biosciences IPO?

(PLSE) raised $20 million in an IPO on Wednesday, May 18th 2016. The company issued 5,000,000 shares at $4.00 per share. MDB Capital Group and Feltl and Company served as the underwriters for the IPO.

What is Pulse Biosciences' stock symbol?

Pulse Biosciences trades on the NASDAQ under the ticker symbol "PLSE."

Who are Pulse Biosciences' major shareholders?

Pulse Biosciences' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (1.52%), Westside Investment Management Inc. (0.39%), Griffin Asset Management Inc. (0.23%), Spotlight Asset Group Inc. (0.18%), Ergoteles LLC (0.10%) and Belvedere Trading LLC (0.00%). Insiders that own company stock include Kevin Patrick Danahy, Maky Zanganeh and Mitchell E Levinson.
View institutional ownership trends
.

How do I buy shares of Pulse Biosciences?

Shares of PLSE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Pulse Biosciences' stock price today?

One share of PLSE stock can currently be purchased for approximately $1.93.

How much money does Pulse Biosciences make?

Pulse Biosciences (NASDAQ:PLSE) has a market capitalization of $71.85 million and generates $1.42 million in revenue each year. The company earns $-63,660,000.00 in net income (profit) each year or ($2.03) on an earnings per share basis.

How many employees does Pulse Biosciences have?

The company employs 142 workers across the globe.

How can I contact Pulse Biosciences?

Pulse Biosciences' mailing address is 3957 POINT EDEN WAY, HAYWARD CA, 94545. The official website for the company is www.pulsebiosciences.com. The company can be reached via phone at (510) 906-4600 or via email at ir@pulsebiosciences.com.

This page (NASDAQ:PLSE) was last updated on 12/2/2022 by MarketBeat.com Staff